ARK Genomic Revolution ETF Rating $25.25 +1.64 (+6.96%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$25.43 +0.18 (+0.70%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock ARK Genomic Revolution ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.ARKG Aggregate RatingModerate Buy 2.68Holdings in ARKG have an aggregate rating of Moderate Buy based on 306 analyst ratings issued in the past year covering 25 companies (90.8% of the portfolio).ARKG Aggregate Price Target$25.25High Prediction$25.25Average Prediction$25.25Low Prediction$25.25Holdings in ARKG have an aggregate price target of $25.25 and a range of $25.25 to $25.25 covering 25 companies (90.8% of the portfolio).ARKG Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ARK Genomic Revolution ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 ARKG Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.21%TEMTempus AI$80.52+5.0%1.9512 of 5 stars2.50$67.64 -16.0%12Trending NewsAnalyst ForecastInsider Trade9.81%CRSPCRISPR Therapeutics$54.32+2.8%3.8063 of 5 stars2.50$71.60 31.8%165.86%TWSTTwist Bioscience$28.59+8.0%4.1661 of 5 stars2.73$49.40 72.8%11Positive News5.72%RXRXRecursion Pharmaceuticals$4.94+3.3%2.5538 of 5 stars2.33$7.00 41.7%6News CoverageInsider Trade4.69%GHGuardant Health$61.40+0.2%3.2374 of 5 stars3.06$57.50 -6.4%17News CoveragePositive News4.49%NTRANatera$165.60+2.3%3.4198 of 5 stars3.06$193.19 16.7%18Positive News4.25%TXG10x Genomics$14.30+9.2%3.6171 of 5 stars2.38$13.54 -5.3%134.00%ADPTAdaptive Biotechnologies$13.00+2.9%2.4324 of 5 stars2.88$12.38 -4.8%8Analyst Revision3.65%SDGRSchrodinger$20.32+3.8%3.1095 of 5 stars2.67$27.83 37.0%63.64%ILMNIllumina$101.80+2.5%4.6591 of 5 stars2.25$124.58 22.4%20Positive News3.59%PSNLPersonalis$4.83+3.6%4.0899 of 5 stars3.00$7.42 53.6%5News Coverage3.38%VCYTVeracyte$31.00+5.3%2.8427 of 5 stars2.70$40.90 31.9%10News Coverage3.27%BEAMBeam Therapeutics$16.64+3.9%2.2581 of 5 stars3.07$48.45 191.2%143.00%ABSIAbsci$2.63+2.7%2.8829 of 5 stars3.00$7.98 203.3%52.91%NTLAIntellia Therapeutics$10.52+3.8%4.6237 of 5 stars2.58$29.05 176.2%19Positive NewsInsider Trade2.80%ARCTArcturus Therapeutics$18.51+5.9%3.1409 of 5 stars3.00$50.57 173.2%8Analyst Forecast2.69%IONSIonis Pharmaceuticals$42.69-1.3%4.653 of 5 stars2.86$60.85 42.5%14Trending NewsAnalyst ForecastInsider Trade2.51%CDNACareDx$12.97+3.7%4.3227 of 5 stars2.67$27.67 113.3%6Positive News1.48%NRIXNurix Therapeutics$10.14+5.1%2.6294 of 5 stars2.81$28.87 184.7%161.47%PRMEPrime Medicine$3.55+10.2%2.8913 of 5 stars2.75$8.92 151.2%8Gap Up1.40%AMGNAmgen$293.72-0.7%4.7093 of 5 stars2.33$303.76 3.4%21Trending NewsInsider Trade1.39%PACBPacific Biosciences of California$1.38+9.5%2.2663 of 5 stars2.43$1.90 37.7%7Positive News1.26%INCYIncyte$85.04-1.7%4.7198 of 5 stars2.33$81.60 -4.0%18Trending NewsAnalyst Forecast1.21%MASS908 Devices$6.45+7.1%2.7013 of 5 stars3.25$8.00 24.0%4Analyst Upgrade1.15%VEEVVeeva Systems$291.03+3.1%3.9539 of 5 stars2.50$274.17 -5.8%24News CoveragePositive NewsUpcoming Earnings This page (BATS:ARKG) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access